The Ottawa Hospital Research Institute and Cancer Center
Welcome,         Profile    Billing    Logout  
 11 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arnaout, Angel
INVINCIBLE, NCT04781725: TRIAL: Intratumoral INT230-6 in Breast Cancer

Recruiting
2
90
Canada
INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection
Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research
Breast Cancer
03/22
03/23
NCT05967884: PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Not yet recruiting
2
20
Canada
Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Ottawa Hospital Research Institute, Ontario Institute for Cancer Research
Breast Cancer
08/24
08/24
NCT03959709: Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction

Recruiting
N/A
56
Canada
immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement., Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement
Ottawa Hospital Research Institute
Mastectomy, Breast Cancer
12/22
12/23
Awan, Arif
INVINCIBLE, NCT04781725: TRIAL: Intratumoral INT230-6 in Breast Cancer

Recruiting
2
90
Canada
INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection
Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research
Breast Cancer
03/22
03/23
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
NCT05601440: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
2
484
Canada
RP-6306, Lunresertib, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, Camonsertib
Canadian Cancer Trials Group
Breast Cancer
12/27
06/28
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT04564079: An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

Recruiting
N/A
100
Canada
Exactis Innovation
NSCLC
07/23
08/23
NCT02355171: Personalize My Treatment (PMT) Registry

Recruiting
N/A
10000
Canada
Exactis Innovation
Cancer
07/25
07/25
BEACON, NCT05804578: Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

Recruiting
N/A
150
Canada
Dr. Christopher Mueller, Canadian Institutes of Health Research (CIHR), Queen's University
Metastatic Breast Cancer
01/26
04/26

Download Options